Results 91 to 100 of about 10,833,331 (248)

Temporal Reproducibility of a Genetic Algorithm-Derived Health Risk Score: Standardized Out-of-Fold Validation Framework (2021-2023). [PDF]

JMIR Bioinform Biotechnol
Aoki Y, Takeda H, Yokota K, Yoshida R.
europepmc   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Development of the UK Rheumatology Occupational Therapy Capabilities Framework: a national consensus initiative. [PDF]

Rheumatol Adv Pract
Prior Y, Gregory WJ, Battista S, Bisset P, Derham S, Dockrell DM, Livesey C, Lyle S, Munakhya S, Murphy R, O'Callaghan G, O'Donnell K, Perkins J, Pidgeon C, Steer H, Tuson S, Walker E, Williams G.   +17 more
europepmc   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

The SALVADOR simulation framework [PDF]

, 2016
Arumi Delgado, Daniel, Manich Bou, Salvador, Weiner, Michael   +2 more
core  

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Hybrid expert system for robust detection of rare sequence signals: a computational proof-of-concept in host-dominated backgrounds. [PDF]

Front Microbiol
Wang S, Xie L, Yan Z, Ma J, Zhao R.
europepmc   +1 more source

Common Assessment Framework [PDF]

, 2004

core  

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Dynamic machine learning approach for workload prediction in cloud environments. [PDF]

Sci Rep
Nashaat M, Moussa W, Rizk R, Saber W.
europepmc   +1 more source